-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>
Yifu Sha ® (domestic commonly known as "Eph medicine") is the treatment of advanced lung cancer is the third-generation EGFR-TKI drugs, the original research of our national class of drugs
Lung cancer is the malignant tumor with the highest incidence and fatality rate in China
The third-generation EGFR-TKI can penetrate the blood-brain barrier and show higher efficacy in the treatment of NSCLC patients with brain metastases.
Yifu Sha ® results registered clinical studies submitted by the State Drug administration show that brain metastases in patients with lung cancer received daily 80mg Yifu Sha ® after treatment, all patients with brain tumor lesions shrink or not grow
Yifu Sha ® enter the health insurance directory will significantly reduce the financial burden of treating patients with lung cancer in China, so that more Chinese patients receive a survival benefit from Chinese original drugs, especially in lung cancer patients with brain metastases let live longer and better
In November this year, Yifu Sha ® treatment was not previously accept the Phase III clinical study of the treatment of EGFR mutation-positive advanced NSCLC successful results, compared to the previous generation EGFR-TKI gefitinib (Iressa) treatment in the control group, "Vladimir medicine "The treatment group can bring significantly longer progression-free survival (PFS) benefits, and PFS is expected to double
In 2022, it is hoped that China's "Fuyao" will bring more Chinese patients the gospel of long-term survival and a better life
